诺华口服新药「伊普可泮」在中国拟纳入优先审评
在全球范围内，伊普可泮在2023年12月获得美国FDA批准上市，成为治疗成人阵发性夜间血红蛋白尿症（PNH）的首个口服单药疗法。今年8月8日，FDA再次批准伊普可泮新适应症，用于降低成人IgA肾病（IgAN）患者的蛋白尿水平，这些患者有疾病迅速进展的 ...
Novartis not joining the 'frenzy' of weight loss drugs, CEO says
Swiss pharmaceutical giant Novartis said Wednesday that it does not plan to enter into the "frenzy" of weight loss drugs.
biopharma-reporter4 天
Novartis’ Kisqali receives FDA approval to reduce the risk of breast cancer recurrence
Novartis announced this week that the FDA has approved ribociclib (marketed as Kisqali) for the treatment of people with ...
Novartis CEO says FDA's extended approval of breast cancer drug is a 'landmark' for the firm
Vas Narasimhan, CEO of Novartis, comments on the progress of the firm's Kisqali metastatic breast cancer drug after the ...
每日经济新闻 on MSN3 天
九洲药业：公司服务客户包括 Novartis、Roche、Zoetis、Gilead等国际知名 ...
每经AI快讯，有投资者在投资者互动平台提问：请问吉利德是否为公司重要客户？有提供了哪些产品和服务吗？谢谢 九洲药业（603456.SH）9月20日在投资者互动平台表示，公司服务客户包括 ...
Novartis股票面临Kisqali专利诉讼的尾部风险 - 美银证券
周三，美银证券调整了对Novartis (NOVN:SW) (NYSE: NVS)股票的立场，将这家制药巨头的评级从买入下调至中性。该公司还修改了Novartis的目标价，将其从之前的110.00瑞士法郎下调至110.00瑞士法郎。这一评级变化是在Novartis相对于其欧洲制药同行表现出色之后做出的。 自2023年初以来，Novartis因一系列成功的III期试验和持续超出预期的盈利而备受关注， ...
Novartis Breast Cancer Drug Helped Delay Return of Disease
Novartis AG’s breast cancer drug helped prevent the disease coming back a year after treatment had ended, in new data that ...
Novartis Breast Cancer Drug Found To Cut Disease Recurrence
Novartis said its Kisqali breast cancer drug produced longer success for those with certain forms of the disease.
Novartis' Multiple Sclerosis Drug Data Shows Most Patients Remain With No Disability ...
Novartis' new data for Kesimpta showed reduced disability progression in relapsing multiple sclerosis patients. Continuous ...
STAT5 天
FDA awards Novartis expanded approval for breast cancer therapy
The potential market for the Novartis drug Kisqali could grow markedly, now that certain early-stage breast cancer patients ...
FiercePharma6 天
Novartis heaps pressure on Lilly with broad FDA approval for Kisqali in early breast cancer
An FDA approval has officially lifted the curtain on a blockbuster market showdown between Novartis and Eli Lilly in early ...
Novartis6 天
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early ...
Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for CDK4/6 inhibitor adjuvant therapy1,2 Kisqali® ...